Although previous clinical trials have demonstrated that antiangiogenetic chemotherapy is not effective in GBM, researchers conducted a retrospective of review of perfusion MR images to determine if a phenotypic subtype of GBM may respond to antiangiogenic chemotherapy.
An analysis of data from caregivers and patients participating in a longitudinal study funded by the National Institutes of Health examines whether caregivers' anxiety, depressive symptoms, burden, and mastery influence survival for patients with newly diagnosed glioblastoma multiforme.
Insurance status influences overall patient survival for some cancer types, but its impact on glioblastoma multiforme (GBM) survival is well documented. This research study explored the possible impact of insurance on GBM survival.
Gross total resection to treat glioblastoma multiforme (GBM) showed progression-free survival benefits over subtotal resection and biopsy in a meta-analysis of 37 studies.
Discovery might eventually lead to better treatment for glioblastoma multiforme
Valproic acid and levetiracetam do not improve survival outcomes in patients with newly diagnosed glioblastoma, according to a recently published study.
Researchers identified propentofylline as a drug that could help treat patients with the deadly brain cancer glioblastoma multiforme.
A tumor's DNA composition plays a key role in whether a glioma may transform into a more serious glioblastoma.
Researchers have found that bevacizumab-induced hypertension may be a predictive marker of improved outcomes in patients with recurrent glioblastoma who are treated with bevacizumab.
Glioblastoma multiforme (GBM) is one of the most lethal primary brain tumors, but new therapeutic strategies are being investigated.
Final results from a phase 2 study show that adding Prophage autologous cancer vaccine to the standard-of-care treatment for newly diagnosed GBM improves survival.
Is there a difference in dosing (1 hour prior to radiotherapy vs bedtime) with temozolomide plus radiotherapy for glioblastoma multiforme?
First-of-its-kind research shows promise for developing a method to clearly identify cancerous tissue during surgery. These findings may potentially improve outcomes for those undergoing surgery to remove glioblastoma multiforme.
Researchers have also created an experimental vaccine to attack immune system targets related to cancer stem cells, the cells from which malignant brain tumors are believed to originate and regenerate.
Patients with recurrent GBM treated with an experimental vaccine made from the patient's own resected tumor tissue showed an improved survival compared with historical patients who received the standard of care alone, according to an analysis of a phase 2 trial of this vaccine.
A prominent protein activated by inflammation is the key instigator that converts glioblastoma multiforme cells to their most aggressive, untreatable form and promotes resistance to radiation therapy.
Attacking glioblastoma brain tumor cells with a modified poliovirus is showing encouraging early results in an ongoing study.
Combining the antiangiogenic bevacizumab with the kinase inhibitor dasatinib stopped glioblastoma metastasis after shrinking the tumors.
Fluorescence form 5-aminolevulinic acid (5-ALA) has been used to guide resection of recurrent GBM. Before surgery, the patient ingests 5-ALA, then the tumor cells fluoresce intraoperatively in response to certain wavelengths of light.
ELTD1, a protein linked with angiogenesis, is the strongest candidate for a significant association with glioma out of nearly 200 possible markers.
Patients with aggressive brain tumors can be effectively treated with smaller radiation fields to spare the rest of the brain and preserve cognition.
Glioblastoma multiforme tumors can originate not only from the glial cells that make up the supportive tissue of the brain and from neural stem cells, but also from other types of differentiated cells in the nervous system, including cortical neurons.
A controlled fasting period lasting no more than 48 hours improved the effectiveness of chemotherapy and radiation therapy in mice with gliomas.
Persons with more than one glioblastoma tumor upon diagnosis experience significantly worse survival than do patients with a solitary lesion.
A slower-growing set of glioblastoma multiforme cells appears to be the source of the brain cancer's recurrence following standard drug therapy.
New research is showing that sequence and timing have significant impact on the efficacy of therapeutic regimens that include bevacizumab.
Medications were able to block a newly identified cancer-promoting pathway and delay glioma growth in mice, suggesting a new treatment option to combat malignant glioma.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Decipher Genomic Classifier Prognostic for Distant Prostate Metastasis
- GUCS 2017: Adjuvant Trials in Post-radical Prostatectomy Prostate Cancer Feasible
- Annual Screening of High-Risk Smokers Only More Cost-effective Than Current Methods
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Metronomic Chemotherapy: Improved Tumor Blood Supply Leads to Better Treatment
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|